title: [Pharmacological agents and transport nanosystems based on plant phospholipids].
abstract: A new generation of plant phosphatidylcholine (PC)-based pharmacological agents has been developed under academician A.I. Archakov leadership at the Institute of Biomedical Chemistry (IBMC). For their production a unique technology allowing to obtain dry lyophilized phospholipid nanoparticles of 30 nm was elaborated. The successful practical application of PC nanoparticles as a drug agent may be illustrated by Phosphogliv (oral and injection formulations). Being developed at IBMC for the treatment of liver diseases, including viral hepatitis, Phosphogliv (currently marketed by the "Pharmstandard" company) is approved for clinical application in 2000, and is widely used in medical practice. Based on the developed and scaled in IBMC technology of prerparation of ultra small size phospholipid nanoparticles without the use of detergents/surfactants and stabilizers another drug preparation, Phospholipovit, exhibiting pronounced hypolipidemic properties has been obtained. Recently completed preclinical studies have shown that PC nanoparticles of 20-30 nm activate reverse cholesterol transport (RCT) and in this context it is more active than well known foreign preparation Essentiale. Phospholipovit is now at the stage of clinical trials (phase 1 completed). PC was also used as a basis for the development of a transport nanosystem with a particles size of 20-25 nm in diameter and incorporation of various drug substances from various therapeutic groups. Using several drugs substances as an example, increased bioavailability and specific activity were demonstrated for the formulations equipped with such transport nanosystem. Formulations equipped with the transport nanosystems have been developed for such pharmacological agents as doxorubicin, rifampin, budesonide, chlorin E6, prednisone, and others.
authors.affiliation: Institute of Biomedical Chemistry, Moscow, Russia.
authors.forename: N V
authors.initials: NV
authors.lastname: Medvedeva
authors.affiliation: Institute of Biomedical Chemistry, Moscow, Russia.
authors.forename: V N
authors.initials: VN
authors.lastname: Prosorovskiy
authors.affiliation: Institute of Biomedical Chemistry, Moscow, Russia.
authors.forename: D V
authors.initials: DV
authors.lastname: Ignatov
authors.affiliation: Institute of Biomedical Chemistry, Moscow, Russia.
authors.forename: O S
authors.initials: OS
authors.lastname: Druzilovskaya
authors.affiliation: Institute of Biomedical Chemistry, Moscow, Russia.
authors.forename: V A
authors.initials: VA
authors.lastname: Kudinov
authors.affiliation: IBMC-EcoBioPharm LLC, Moscow, Russia.
authors.forename: E O
authors.initials: EO
authors.lastname: Kasatkina
authors.affiliation: Institute of Biomedical Chemistry, Moscow, Russia.
authors.forename: E G
authors.initials: EG
authors.lastname: Tikhonova
authors.affiliation: Institute of Biomedical Chemistry, Moscow, Russia.
authors.forename: O M
authors.initials: OM
authors.lastname: Ipatova
mesh_terms: D000818:Animals; D001682:Biological Availability; D002784:Cholesterol / Q000378:metabolism; D004317:Doxorubicin / Q000008:administration & dosage; D004337:Drug Carriers; D004338:Drug Combinations; D016503:Drug Delivery Systems; D015195:Drug Design; D019695:Glycyrrhizic Acid / Q000737:chemistry / Q000494:pharmacology*; D006801:Humans; D053758:Nanoparticles / Q000737:chemistry; D049329:Nanostructures / Q000737:chemistry*; D010316:Particle Size; D010713:Phosphatidylcholines / Q000737:chemistry / Q000494:pharmacology*; D010743:Phospholipids / Q000737:chemistry*; D012293:Rifampin / Q000008:administration & dosage
chemical_list: D004337:Drug Carriers; D004338:Drug Combinations; D010713:Phosphatidylcholines; C504418:Phosphogliv; D010743:Phospholipids; D019695:Glycyrrhizic Acid; D004317:Doxorubicin; D002784:Cholesterol; D012293:Rifampin
keywords: drug delivery nanosystem; phosphatidylcholine; phospholipid nanoparticles; targed delivery